Dendritic cell–derived EVs carry all the functionally active molecules needed for the activation and the induction of anti-tumor T-cell immune responses (complexes of MHC class I and II with tumor antigens, as well as co-stimulatory and adhesion molecules such as CD80, CD86, and CD40) (114) and can act alone as cell-free anti-tumor vaccines. The gene discussed is CD86; the disease is neoplasm.